Jiangsu Medomics Medical Technology Co., Ltd., founded in October 2017, is located at Biotech and Pharmaceutical Valley of the National Jiangbei New Area, Nanjing, Jiangsu Province. It is a international high-tech enterprise driven by innovation in the area of medical devices R&D, production and sales. Medomics focuses on diagnosis of microorganisms, tumors and some rare diseases, mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and automatic instruments.
Medomics owns two R&D centers in China and the US, independent intellectual property rights of fluorescent staining technology, protein labeling technology, time-resolved immunofluorescence detection technology, image processing and analysis technology and other innovative technology platforms, as well as a total of more than 2,000 square meters of GMP purification production workshop that meets the product standards of FDA, CE and CFDA. Medomics also has a multidisciplinary expert team with abundant experience in the industry, including senior experts in immunology, microbiology, applied physics, polymer materials, medical imaging, optical systems, etc. The members of the technical team are led by doctors from many famous institutions, such as Osaka University, North Carolina University, University of Nebraska Lincoln, Zhejiang University, Sichuan University and other institutions.
At the very beginning of COVID-19 on early 2020, Medomics developed IgM/IgG antibody detecting kit with the team of Zhong Nanshang. And Medomics published the first research paper on international journal together with State Key Laboratory of Respiratory Disease (National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health). The detecting kit was validated by CDC, Harvard Medical School and Columbia University Irving Medical Center etc. Until May 2020, the kit has been exported to dozens of countries and areas, making great help against SARS-Cov-2.
At present, Medomics’s series product of SARS-Cov-2 detection have been developed according to ISO 13485 Quality system and European CE Certification.
The company was established in
1650Ten thousand yuan
40+Countries and regions
Antibody detection kit has been exported
In China, R & D, production and sales integration operation, actively explore the broad Chinese market; American companies carry out research and development of cutting-edge technology, as well as the introduction of advanced products, and expand international sales channels.
With the global original technology, it provides the overall solution of rapid clinical diagnosis for gynecology and pediatrics, covering the fields of gynecological infection detection, gynecologic tumor detection and pregnancy monitoring. At the same time, we focus on the global frontier market of detection reagents and provide customers with overall covid-19 solutions.
Innovation responsibility service values
At present, Mecca has passed the ISO13485 quality system certification of international well-known institutions, and the new crown series products have obtained the EU CE certification.
The company has independent intellectual property rights of fluorescent staining technology, protein labeling technology, time-resolved immunofluorescence detection technology, image processing and analysis technology and other innovative technology platforms, as well as a total of more than 2000 square meters of GMP purification production workshop in line with FDA, CE, CFDA product standards
Jiangsu Medomics Medical Technology Co., Ltd.,establish.
Round a financing
GMP workshop completed
Gynecological infection detection kit and cervical cancer detection kit were used.
The staining instrument was used to get the certificate.
We have successfully developed covid-19 antibody detection kit, formed a mass production well, and published the world's first SCI paper on new coronal antibody detection.
It has passed BSI is013485:2016 medical device quality management system certification.
July: successfully developed covid-19 antigen detection and neutralization antibody detection kit.
Integrity: we must demand ourselves, partners and each other with the highest moral and integrity standards. We are committed to diversity, fair treatment, mutual respect and mutual trust. Responsibility: we keep our promises to our customers, shareholders and each other. Take responsibility for actions and outcomes, and hope others will do the same. Collaboration: we create and encourage an environment for success through continuous innovation, continuous learning, excellence and collaboration. Our leadership philosophy is to motivate and promote employee participation and focus on career development. We advocate open communication and interaction. Innovation: we recognize that continuous innovation for our customers is the cornerstone of our business. In the customer service and other work, we face the difficulties and strive to create new and better methods. We encourage, expect and value the spirit of innovation, prudent risk-taking, open innovation and diversified perspectives.